The DSMB safety recommendation is a minor positive for the pipeline, but the stock has extremely low market cap ($5M) and high historical volatility. Monitor for future patient enrollment updates and any regulatory interactions. No financial impact expected near term.
Price Chart
Executive Summary
60 Degrees Pharmaceuticals announced that the independent Data Safety Monitoring Board recommended continuation of its B-Free chronic babesiosis study after reviewing safety data from the first six patients. The study evaluates the ARAKODA (tafenoquine) regimen in patients with severe persistent fatigue and babesiosis exposure, an area with no FDA-approved treatment.
Key Facts
- DSMB recommended continuation of B-Free chronic babesiosis study after safety review of first 6 patients through Day 30
- B-Free study evaluates ARAKODA (tafenoquine) regimen for chronic babesiosis-related fatigue in up to 100 patients
- No FDA-approved treatment or vaccine exists for babesiosis
- Tafenoquine is FDA-approved only for malaria prophylaxis, not for babesiosis
Financial Impact
No financial figures disclosed; trial continuation is a modest derisking signal but no revenue implications in near term.
Risk Factors
- Tafenoquine is not approved for babesiosis; eventual regulatory path is uncertain
- Study may fail to meet primary endpoints
- Going-concern risk previously disclosed by the company
- Low market cap and liquidity create outsized price moves on small news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3320572 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.8759 | awaiting T+5 | — | $0.8700 (−0.67%) |
Oct 6, 2026 20d ago | Press Release | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Oct 6, 2026 20d ago | 8-K | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Aug 26, 2026 8w ago | EFFECT | $1.08 $0.9495 | ▲ +12.08% | ▲ +11.96% | $0.8700 (+19.44%) |
Aug 14, 2026 10w ago | Press Release | $1.20 $1.13 | ▲ +5.44% | ▲ +4.07% | $0.8700 (+27.20%) |
Jul 30, 2026 12w ago | Press Release | $1.25 $1.15 | ▲ +8.00% | ▲ +11.62% | $0.8700 (+30.40%) |
Jul 1, 2026 16w ago | Press Release | $1.75 $1.55 | ▼ −11.43% | ▼ −11.38% | $0.8700 (−50.29%) |
May 26, 2026 21w ago | Press Release | $1.50 $1.46 | ▼ −2.67% | ▼ −3.75% | $0.8700 (−42.00%) |
May 15, 2026 23w ago | Press Release | $1.39 $1.48 | ▼ −6.47% | ▼ −5.51% | $0.8700 (+37.41%) |
Mar 31, 2026 29w ago | Press Release | $1.75 $1.81 | ▲ +3.43% | ▼ −0.52% | $0.8700 (−50.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers